众生药业
(002317)
| 流通市值：103.50亿 | | | 总市值：115.73亿 |
| 流通股本：7.62亿 | | | 总股本：8.52亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 766,131,361.53 | 971,641,672.77 | 954,601,790.51 | 1,252,043,320.29 |
| 结算备付金 | 0 | 0 | 0 | 0 |
| 拆出资金 | 0 | 0 | 0 | 0 |
| 衍生金融资产 | 0 | 0 | 0 | 0 |
| 应收票据及应收账款 | 1,030,733,355.47 | 1,105,924,854.42 | 1,214,479,264.39 | 978,293,306.04 |
| 其中：应收票据 | 449,432,196.41 | 542,359,529.92 | 726,792,847.02 | 497,755,507.56 |
| 应收账款 | 581,301,159.06 | 563,565,324.5 | 487,686,417.37 | 480,537,798.48 |
| 应收款项融资 | 740,000 | 0 | 3,200 | 3,200 |
| 预付款项 | 84,724,481.2 | 89,186,182.38 | 92,193,298.46 | 87,339,579.02 |
| 应收保费 | 0 | 0 | 0 | 0 |
| 应收分保账款 | 0 | 0 | 0 | 0 |
| 应收分保合同准备金 | 0 | 0 | 0 | 0 |
| 其他应收款合计 | 18,786,244.49 | 17,108,193.73 | 15,452,551.41 | 16,521,233.75 |
| 其中:应收利息 | 0 | 0 | 0 | 0 |
| 应收股利 | 0 | 0 | 0 | 0 |
| 买入返售金融资产 | 0 | 0 | 0 | 0 |
| 存货 | 483,679,034.01 | 504,835,619.25 | 490,500,491.65 | 520,393,304.89 |
| 合同资产 | 0 | 0 | 0 | 0 |
| 一年内到期的非流动资产 | 162,385,831.93 | 129,198,023.71 | 177,938,427.39 | 307,886,471.21 |
| 其他流动资产 | 102,314,390.88 | 101,277,325.16 | 114,575,292.07 | 115,066,036.01 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 3,260,603,051.47 | 3,208,680,366.28 | 3,566,392,507.42 | 3,960,606,763.22 |
| 非流动资产: | | | | |
| 发放委托贷款及垫款 | 0 | 0 | 0 | 0 |
| 债权投资 | 0 | 0 | 0 | 0 |
| 其他债权投资 | 0 | 0 | 0 | 0 |
| 长期应收款 | 0 | 0 | 0 | 0 |
| 长期股权投资 | 3,653,444.06 | 4,195,591.32 | 2,554,485.08 | 1,815,466.82 |
| 其他权益工具投资 | 121,848,333.67 | 122,138,426.84 | 123,039,292.97 | 122,334,252.37 |
| 其他非流动金融资产 | 34,765,000 | 34,765,000 | 34,765,000 | 34,765,000 |
| 投资性房地产 | 14,544,906.07 | 3,267,408.44 | 3,366,359.14 | 3,465,309.86 |
| 固定资产 | 667,009,547.04 | 688,895,983.48 | 557,191,498.92 | 569,098,281.27 |
| 在建工程 | 11,059,418.56 | 5,262,782.41 | 124,476,748.56 | 123,548,723.01 |
| 生产性生物资产 | 0 | 0 | 0 | 0 |
| 油气资产 | 0 | 0 | 0 | 0 |
| 使用权资产 | 1,530,207.27 | 2,107,655.52 | 2,685,103.77 | 3,262,552.02 |
| 无形资产 | 422,638,526.24 | 434,915,243.96 | 440,355,893.12 | 446,699,182.02 |
| 开发支出 | 632,977,582.34 | 616,941,056.5 | 559,788,107.95 | 538,349,981.64 |
| 商誉 | 208,626,197.09 | 208,626,197.09 | 208,626,197.09 | 208,626,197.09 |
| 长期待摊费用 | 1,986,442.13 | 2,277,899.67 | 2,925,751.32 | 3,363,868.47 |
| 递延所得税资产 | 49,250,395.65 | 45,984,040.6 | 43,852,229.31 | 42,447,640.12 |
| 其他非流动资产 | 389,553,395.62 | 412,352,262.31 | 555,415,768.53 | 400,139,181.18 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,559,443,395.74 | 2,581,729,548.14 | 2,659,042,435.76 | 2,497,915,635.87 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,820,046,447.21 | 5,790,409,914.42 | 6,225,434,943.18 | 6,458,522,399.09 |
| 流动负债: | | | | |
| 短期借款 | 0 | 0 | 328,852,473.56 | 621,487,515.16 |
| 向中央银行借款 | 0 | 0 | 0 | 0 |
| 吸收存款及同业存放 | 0 | 0 | 0 | 0 |
| 拆入资金 | 0 | 0 | 0 | 0 |
| 交易性金融负债 | 0 | 0 | 0 | 0 |
| 衍生金融负债 | 0 | 0 | 0 | 0 |
| 应付票据及应付账款 | 110,543,621.17 | 138,966,930.91 | 111,086,333.1 | 93,784,128.75 |
| 其中：应付票据 | 16,349,273.75 | 33,579,823 | 9,000,000 | 9,000,000 |
| 应付账款 | 94,194,347.42 | 105,387,107.91 | 102,086,333.1 | 84,784,128.75 |
| 预收款项 | 107,364.56 | 8,850.2 | 76,800 | 0 |
| 合同负债 | 26,269,307.93 | 21,997,855.45 | 25,922,237.99 | 25,908,682.08 |
| 卖出回购金融资产款 | 0 | 0 | 0 | 0 |
| 应付手续费及佣金 | 0 | 0 | 0 | 0 |
| 应付职工薪酬 | 19,567,148.59 | 18,239,206.92 | 19,121,193.32 | 49,782,404.68 |
| 应交税费 | 65,962,176.64 | 63,057,954 | 53,004,216.88 | 52,650,725.11 |
| 其他应付款合计 | 127,035,020.62 | 178,537,498.87 | 145,324,215.69 | 122,777,966.37 |
| 其中:应付利息 | 0 | 0 | 0 | 0 |
| 应付股利 | 0 | 0 | 0 | 0 |
| 应付分保账款 | 0 | 0 | 0 | 0 |
| 保险合同准备金 | 0 | 0 | 0 | 0 |
| 代理买卖证券款 | 0 | 0 | 0 | 0 |
| 代理承销证券款 | 0 | 0 | 0 | 0 |
| 一年内到期的非流动负债 | 1,613,229.43 | 2,289,150.63 | 100,595,329.21 | 4,811,918.63 |
| 其他流动负债 | 67,234,035.59 | 76,670,556.97 | 41,989,640.16 | 44,110,937.4 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 418,331,904.53 | 499,768,003.95 | 825,972,439.91 | 1,015,314,278.18 |
| 非流动负债: | | | | |
| 长期借款 | 0 | 0 | 0 | 97,000,000 |
| 应付债券 | 0 | 0 | 0 | 0 |
| 优先股 | 0 | 0 | 0 | 0 |
| 永续债 | 0 | 0 | 0 | 0 |
| 租赁负债 | 306,409.04 | 299,604.47 | 638,283.69 | 1,301,733.4 |
| 长期应付款 | 657,828,208.57 | 652,345,399.12 | 644,749,509.06 | 637,610,021.23 |
| 长期应付职工薪酬 | 0 | 0 | 0 | 0 |
| 预计负债 | 0 | 0 | 0 | 0 |
| 递延收益 | 162,243,003.69 | 163,348,113.41 | 131,846,730.58 | 132,668,809.47 |
| 递延所得税负债 | 38,173,024.39 | 31,252,334.61 | 44,004,506.59 | 48,950,943.3 |
| 其他非流动负债 | 0 | 0 | 0 | 0 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 858,550,645.69 | 847,245,451.61 | 821,239,029.92 | 917,531,507.4 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,276,882,550.22 | 1,347,013,455.56 | 1,647,211,469.83 | 1,932,845,785.58 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 851,556,477 | 853,350,477 | 853,350,477 | 853,350,477 |
| 其他权益工具 | 0 | 0 | 0 | 0 |
| 优先股 | 0 | 0 | 0 | 0 |
| 永续债 | 0 | 0 | 0 | 0 |
| 资本公积 | 1,800,475,893 | 1,814,236,409.96 | 1,809,946,141.26 | 1,807,101,297.43 |
| 减:库存股 | 8,097,480 | 66,456,772.71 | 67,140,772.71 | 67,140,772.71 |
| 其他综合收益 | 56,914,239.61 | 57,217,033.61 | 57,967,790.38 | 57,362,705.25 |
| 专项储备 | 0 | 0 | 0 | 0 |
| 盈余公积 | 321,501,033.58 | 321,501,033.58 | 321,501,033.58 | 321,501,033.58 |
| 一般风险准备 | 0 | 0 | 0 | 0 |
| 未分配利润 | 1,363,372,423.71 | 1,301,979,777.79 | 1,435,423,758.09 | 1,384,129,891.72 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 4,385,722,586.9 | 4,281,827,959.23 | 4,411,048,427.6 | 4,356,304,632.27 |
| 少数股东权益 | 157,441,310.09 | 161,568,499.63 | 167,175,045.75 | 169,371,981.24 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 4,543,163,896.99 | 4,443,396,458.86 | 4,578,223,473.35 | 4,525,676,613.51 |
| 负债和股东权益合计 | 5,820,046,447.21 | 5,790,409,914.42 | 6,225,434,943.18 | 6,458,522,399.09 |
| 公告日期 | 2024-10-29 | 2024-08-30 | 2024-04-23 | 2024-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |